Additional Proxy Soliciting Materials (definitive) (defa14a)
October 01 2021 - 4:43PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section
13 or 15(d) of the
Securities Exchange
Act of 1934
Date of Report (Date
of earliest event reported): October 1, 2021
AIKIDO
PHARMA INC.
|
(Exact
name of registrant as specified in its charter)
|
Delaware
|
|
000-05576
|
|
52-0849320
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
One
Rockefeller Plaza, 11th Floor,
New York,
NY
|
|
10020
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
|
Registrant’s
telephone number, including area code: (703) 992-9325
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
|
|
|
☒
|
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
Indicate by check mark
whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section
12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock,
$0.0001 par value
|
|
AIKI
|
|
The Nasdaq
Capital Market
|
Item 5.07. Submission of Matters
to a Vote of Security Holders.
AIkido Pharma Inc., a
Delaware corporation (the “Company”) has determined that it will be unable to convene its scheduled annual meeting of stockholders
on October 5, 2020 because it will not receive a sufficient number of votes to form a quorum (>50% of outstanding shares) to take
action under Delaware law and the Company’s bylaws. The annual meeting has been rescheduled for 12:00 p.m. Eastern Standard
Time on November 3, 2021 in order to provide additional time to obtain the votes required to reach a quorum. The Company has received
votes from approximately 34% of the shares outstanding on the August 17, 2021 record date and needs only an additional approximately
17% to convene the meeting.
The annual meeting can
be attended by stockholders using the same access information set forth in the Definitive Proxy Statement filed with the Securities and
Exchange Commission on August 26, 2021.
Item 8.01. Other Events.
The information set forth
in Item 5.07 is incorporated herein by reference.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
AIKIDO PHARMA INC.
|
|
|
|
By:
|
/s/
Anthony Hayes
|
|
Name:
|
Anthony Hayes
|
|
Title:
|
Chief Executive
Officer
|
Dated: October 1, 2021
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Apr 2023 to Apr 2024